GlassScriptPhysician profile
Leanza H Liu
NPI 1215105135
$1,389.16
in general payments reported to CMS, 2019-2025
15 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.84 · 2020: $43.41 · 2021: $234 · 2022: $186 · 2023: $282 · 2024: $259 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741 · Long Term Medical Supply Or Device Loan: $79.92 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.82 |
| Long Term Medical Supply Or Device Loan | $79.92 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $208.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $124.78 | 2022-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Medtronic, INC. | $86.10 | 2021-2023 | Minimed 770g |
| Bayer Healthcare Pharmaceuticals INC. | $79.43 | 2023-2025 | |
| Dexcom, INC. | $61.87 | 2024-2025 | Dexcom G6 Transmitter |
| Acella Pharmaceuticals, LLC | $40.93 | 2025 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $35.25 | 2022 | |
| Medtronic Minimed, INC. | $33.74 | 2019-2020 | |
| Amgen INC. | $31.86 | 2024-2025 | Evenity, Repatha |
| Chiesi USA, INC. | $30.74 | 2025 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $25.57 | 2021 | |
| Cequr Corporation | $20.12 | 2025 | Cequr Simplicity |
| Abbvie INC. | $13.74 | 2021 | |
| Pfizer INC. | $13.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanza Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.